Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of Next-generation Tumor-homing Induced Neural Stem Cells to Enhance Treatment of Metastatic Cancers

ABSTRACT: Development of Next-generation Tumor-homing Induced Neural Stem Cells to Enhance Treatment of Metastatic Cancers

PROVIDER: PRJNA660639 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12562200.fastq.gz	Fastqsanger.gz
	SRR12562201.fastq.gz	Fastqsanger.gz
	SRR12562202.fastq.gz	Fastqsanger.gz
	SRR12562203.fastq.gz	Fastqsanger.gz
	SRR12562204.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 96

Similar Datasets

Development of Next-generation Tumor-homing Induced Neural Stem Cells to Enhance Treatment of Metastatic Cancers

Project description:Engineered tumor-homing neural stem cells (NSCs) have shown promise in treating cancer. Recently, we transdifferentiated skin fibroblasts into tumor-homing early-stage human induced NSCs (hiNSC) as personalized NSC drug carriers. Here, using a SOX2 and spheroidal culture-based reprogramming strategy, we generated a new hiNSC variant, hiNeuroS, that were genetically distinct from fibroblasts and first-generation hiNSCs and possessed significantly enhanced tumor-homing and anti-tumor properties. To understand the transcriptomic profile of cells during our sphere-based generation of hiNeuroS, we performed single-cell RNA sequencing (scRNA-seq). The results showed that, while some of the hiNeuroS cells shared a similar trajectory states with the fibroblasts, there was a unique cell group at the far end of hiNeuroS trajectory towards the latest pseudotime, and suggested our new sphere-based culture methods generate hiNeuroS that are a genetically distinct NSC sub-populations that expresses tumor-homing pathways at levels greater than hiNSC.

2021-04-16 | GSE157253 | GEO

Secretome identification of immune cell factors mediating metastatic cell homing

Project description:Metastatic cell homing is a complex process mediated in part by diffusible factors secreted from immune cells found at a pre-metastatic niche. We report on connecting together secretomics and a TRanscriptional Activity CEll aRray (TRACER) to identify functional paracrine interactions between immune cells and metastatic cells as novel mediators of metastatic cell homing. Splenocytes from orthotopic mouse models of breast cancer were isolated to generate a diseased splenocyte conditioned media (D-SCM) containing immune cell secreted factors. MDA-MB-231 metastatic cell activity including cell invasion, migration, transendothelial migration, and proliferation were increased when cultured with D-SCM compared to healthy SCM (H-SCM) and unconditioned media controls. Our secretome analysis of D-SCM yielded secreted factor candidates that contribute to increased metastatic cell activity. In parallel, we identified active TFs within metastatic cells in response to the secreted factors using TRACER. We connected both data sets using MetaCore software to determine interactions between immune cell secreted factors and active metastatic cell TFs to narrow down functional secreted factor candidates that mediate metastatic cell homing. Haptoglobin was among the list of secreted factors and was validated in vitro as a key mediator of metastatic cell recruitment. Furthermore, we designed an implantable poly(lactide-co-glycolide) biomaterial scaffold as a mimic of the pre-metastatic niche to slowly release haptoglobin and demonstrate increased homing of metastatic cells to the scaffold in vivo. Taken together, our studies demonstrate a novel systems biology technique to identify functional paracrine signaling factors, which were validated to reveal mediators of metastatic cell homing.

2015-12-17 | PXD002051 | Pride

Proteomics profiling in primary tumors of metastatic and non-metastatic breast cancers

Project description:Analysis of different proteomics profile in primary tumors of metastatic and non-metastatic breast cancers.

2023-03-09 | PXD037288 | Pride

Microarray analysis of DNA methylation in metastatic versus non metastatic breast cancers

Project description:19 non-metastatic breast cancers (controls) and 19 breast cancers showing metastases or metastatic relapse within 5 years (cases) were extracted from a multi-institutional case series of 123 breast cancer patients . Cases and controls were analyzed for DNA methylation over 56 genes by the MethDet assay [1]using a dedicated microarray (MethDet56). 1. Levenson VV, Melnikov AA: The MethDet: a technology for biomarker development. Expert Rev Mol Diagn 2011, 11:807-812.

2015-03-20 | E-MTAB-3153 | biostudies-arrayexpress

Differential Mutations In Matched Primary and Metastatic Colorectal Cancers

Project description:Differential Mutations In Matched Primary and Metastatic Colorectal Cancers

| PRJNA314364 | ENA

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers

Project description:Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell lines we demonstrate that a fraction of metastatic ER + BC is highly reliant on oxidative phosphorylation (OXPHOS). Treatment by the OXPHOS inhibitor IACS-010759 strongly inhibits tumour growth in multiple endocrine and palbociclib resistant PDX. Mutations in the PIK3CA/AKT1 genes are significantly associated with response to IACS-010759. At the metabolic level, in vivo response to IACS-010759 is associated with decreased levels of metabolites of the glutathione, glycogen and pentose phosphate pathways in treated tumours. In vitro, endocrine and palbociclib resistant cells show increased OXPHOS dependency and increased ROS levels upon IACS-010759 treatment. Finally, in ER + BC patients, high expression of OXPHOS associated genes predict poor prognosis. In conclusion, these results identify OXPHOS as a promising target for treatment resistant ER + BC patients.

2023-06-27 | MTBLS3342 | MetaboLights

Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers.

Project description:Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers.

| PRJNA427119 | ENA

Ahr-Foxp3-RORγt Axis Controls Gut Homing of CD4+ T Cells by Regulating GPR15

Project description:The orphan chemoattractant receptor GPR15 is important for homing T lymphocytes to the large intestine, thereby maintaining intestinal immune homeostasis. However, the molecular mechanisms underlying the regulation of GPR15 expression remain elusive. Here we show a central role of the aryl hydrocarbon receptor (Ahr) in promoting GPR15 expression both in mice and human, thus gut homing of T lymphocytes. Mechanistically, Ahr directly binds to open chromatin regions of the Gpr15 locus to enhance its expression. Ahr transcriptional activity in directing GPR15 expression was modulated by two transcription factors, Foxp3 and RORγt, both of which are expressed preferentially by gut Tregs in vivo. Specifically, Foxp3 interacted with Ahr and enhanced Ahr DNA binding at the Gpr15 locus, thereby promoting GPR15 expression. In contrast, RORγt plays an inhibitory role at least in part by competing with Ahr binding to the Gpr15 locus. Our findings thus demonstrate a key role for Ahr in regulating Treg intestinal homing under the steady state and during inflammation, and the importance of Ahr-RORγt-Foxp3 axis in regulating gut homing receptor GPR15 expression by lymphocytes.

2020-07-29 | GSE137171 | GEO

Oncogenes overexpressed in metastatic oral cancers from patients with pain: potential pain mediators released in exosomes

Project description:Oral cancer patients experience pain at the site of the primary cancer. Patients with metastatic oral cancers report greater pain. Lack of pain identifies patients at low risk of metastasis with sensitivity = 0.94 and negative predictive value = 0.89. In the same cohort, sensitivity and negative predictive value of depth of invasion, currently the best predictor, were 0.95 and 0.92, respectively. Cancer pain is attributed to cancer-derived mediators that sensitize neurons and is associated with increased neuronal density. We hypothesized that pain mediators would be overexpressed in metastatic cancers from patients reporting high pain. We identified 40 genes overexpressed in metastatic cancers from patients reporting high pain (n=5) compared to N0 cancers (n=10) and normal tissue (n=5). The genes are enriched for functions in extracellular matrix organization and angiogenesis. They have oncogenic and neuronal functions and are reported in exosomes. Hierarchical clustering according to expression of neurotrophic and axon guidance genes also separated cancers according to pain and nodal status. Depletion of exosomes from cancer cell line supernatant reduced nociceptive behavior in a paw withdrawal assay, supporting a role for exosomes in cancer pain. The identified genes and exosomes are potential therapeutic targets for stopping cancer and attenuating pain.

2020-09-07 | GSE156178 | GEO

Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells

Project description:Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells

| PRJNA660961 | ENA